

# Investing in Anti-infective Therapeutics

## Antiviral and Antifungal Compounds

Research Corporation Technologies is looking for companies and technologies that offer promising antiviral and antifungal human therapeutics. We are interested in novel classes of compounds and novel approaches to controlling and eradicating selected viral and fungal diseases. Antiviral therapeutics for hepatitis B and C are of particular interest. We seek:

- Preclinical and early clinical therapeutic candidates
- New chemical entities or novel biologicals
- Novel reformulations of approved drugs for targeted therapeutics

RCT has assets of more than \$300 million to advance technology development activities through flexible, long-term investment options. We focus our investments on opportunities that promise patented biomedical products with a clear competitive advantage.

**If you are a start-up or early-stage company**, RCT invests in companies whose technologies have the potential to become significant biomedical products through our RCT BioVentures program. Our initial financial commitment to our portfolio companies usually ranges from several hundred thousand dollars to several million dollars, and we reserve additional funds for the subsequent funding of successful companies. We can also invest management resources if needed.

**If you have a new therapeutic**, RCT can help it move from bench to bedside. We can provide money and management to advance a promising new drug into clinical trials through a variety of business arrangements, including licenses and development partnerships.

If your company or technology meets our criteria and needs further development and commercialization, we would like to hear from you. Please contact us to begin a confidential review of your opportunity



101 N. Wilmot Road, Suite 600  
Tucson, Arizona 85711-3365  
Telephone: (520) 748-4400  
Fax: (520) 748-0025  
Web: [www.rctech.com](http://www.rctech.com)

**Contact:** Christopher P. Martin, MBA at (520) 748-4465 or [cmartin@rctech.com](mailto:cmartin@rctech.com)